Predictors of mortality among COVID-19 patients in Shebin El Kom Chest Hospital
Keywords:
COVID-19, mortality, PCRAbstract
Background: Determining and classifying predictors of mortality of COVID 19 is of great importance for the most efficient use of healthcare resources and public health guidance and will yield improvement in clinical management and outcomes. Aim of the work: To assess Predictors of mortality among COVID 19 patients. Patients and method: 299 patients of confirmed COVID 19 by PCR rolled in our study each patient underwent detailed history, laboratory investigation, CT chest and treated according to severity regarding to Egyptian Ministry of Health Protocol (MOHP). Result: Univariate analysis revealed that old age (OR 1.061 and P value <0.001) ,ICU admission, (OR 10.052 P value <0.001) HTN (OR 2.412 P value 0.002) ,cardiac diseases (OR 2.687 P value 0.014) tachypnea(OR 1.126 P value 0.002),fever (OR 2.118 P value 0.023) hypoxiemia (OR 0.896 P value <0.001), increased inflammatory markers WBCS( OR 1.080 P value <0.001), CRP(OR 1.015 P value 0.002) ,D-dimer (OR 1.540 P value 0.001) S. Ferritin (OR 1.002 P value 0.002), ESR (OR 1.019 P value <0.001)and corad5 (OR 2.308 P value .250) were predictors for motility while in multivariate analysis elderly patients, tachypnea , hypoxiemia and increased ESR are independent factors of mortality.
Downloads
References
Akcicek M, Ilgar M, Ünlü S. Is anemia a risk factor in pneumonia progression in COVID-19-infected patients?. The Egyptian Journal of Chest Diseases and Tuberculosis. 2022 Jul 1;71(3):277.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med. (2020) 383:1813–26. doi: 10.1056/NEJMoa2007764
Brandão Neto D, Fornazieri MA, Dib C, Di Francesco RC, DotyRL, et al. Chemosensory Dysfunction in COVID-19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample. Otolaryngol Head Neck Surg.2020;164:512---8
Cennimo DJ, Bergman SJ, Olsen KM, Bronze MS, Miller MM.Coronavirus Disease 2019 (COVID-19), Practice Essentials, Background, Route of Transmission. Medscape. Available on https//emedicine. medscape. com/article/2500114-overview. https://monoset. com/blog/journal/a-letter-from-alberteinstein-to-his-daughter-on-the-universal-force-of-love. 2020.
Centers for Disease Control and Prevention. Interim Guidelines for Collecting. Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease. 2019;2020.
Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, et al.SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine. 2021 Jan 21;384(3):229-37.
Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, et al.Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy. medRxiv. 2021 Jan 1.
Coopersmith CM, De Backer D, Deutschman CS, Ferrer R, Lat I, Machado FR, Martin GS, Martin-Loeches I, Nunnally ME, Antonelli M, Evans LE. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive care medicine. 2018 Sep;44(9):1400-26.
Davies NG, Klepac P, Liu Y, Prem K, Jit M, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 2020; 26:1205–1211.
Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020; 55: 2000524 [https://doi.org/10.1183/13993003.00524-2020].
Elmorshedy RM, El-Kholy MM, Moniem AE, Hassan SA, Sadek SH. Can simple blood markers predict the outcome of coronavirus disease 2019 (COVID-19) infection?. The Egyptian Journal of Chest Diseases and Tuberculosis. 2022 Jul 1;71(3):271.
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. New England Journal of Medicine. 2020 Oct 29;383(18):1757-66.
Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L, Carlesso E, Castelli G, Cattaneo S. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA internal medicine. 2020 Oct 1;180(10):1345-55.
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal. 2020 May 1;55(5).
Guan WJ, Ni ZY, Hu Y, Liang W, Ou CQ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–1720.
Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PAE,et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenomacarcinoma sequence during colorectal cancer progression. J Pathol 2003; 200:183–194.
Henry BM, De Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Jul 1;58(7):1021-8.
Henry BM, De Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Jul 1;58(7):1021-8.
Hopkins C, Vaira LA, De Riu G. Self-reported olfactory loss inCOVID-19: is it really a favorable prognostic factor? Int ForumAllergy Rhinol. 2020;10:926.
Hsu CY, Lai CC, Yen AMF, Chen SLS, Chen HH. Efficacy of Remdesivir in COVID-19 patients with a simulated two-arm controlled study. medRxiv .doi: 10.1101/2020.05.02.20088559
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
Hui DS, Azhar IE, Madani TA, Ntoumi F, Kock R, et al. The continuing 2019-nCoV epidemicthreat of novel coronaviruses to global health – The latest 2019 novel coronavirusoutbreak in Wuhan, China. Int J Infect Dis 2020; 91:264–266.
Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID‐19. Viruses. 2021;13(4):628. 32. Corti D, Purcell LA, Snell G, Veesler D. Tackling COVID‐19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086‐3108. 33.
Ibrahim DA, Hassan TH. Prediction of development of disease among contacts of COVID-19 patients. The Egyptian Journal of Chest Diseases and Tuberculosis. 2022 Jul 1;71(3):283.
Islam MS, Rahman KM, Sun Y, Qureshi MO, Abdi I, Chughtai AA, Seale H. Current knowledge of COVID-19 and infection prevention and control strategies in healthcare settings: A global analysis. Infection Control & Hospital Epidemiology. 2020 Oct;41(10):1196-206.
Kim S, Lee S, Trang KTT, Kim SH, Kim IH, et al. Parthenolideexerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer. Int J Mol Med 2014; 33:1261–1267.
Konukoglu D, Uzun H. Endothelial dysfunction and hypertension.Hypertension 2016; 511–540.
Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. Journal of internal medicine. 2001 Feb;249(S741):61-74.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England journal of medicine. 2020 Jan 29.
Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials. Journal of medical virology. 2022 May;94(5):2222-9.
Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 inelderly patients: a comparison with young and middle-aged patients. J Inf Secur. 2020;15(30):1–5 [Accessed April 18, 2020https://www.journalofinfection.com/article/S01634453(20)30116- X/pdf].
Mahmoud MA, Khaleel WG, Medhat MA, Hosni A, Kasem AH, Ramadan HK. Can hematologic inflammatory parameters predict the severity of coronavirus disease 2019 at hospital admission?. The Egyptian Journal of Chest Diseases and Tuberculosis. 2022 Jul 1;71(3):265.
Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nature reviews Gastroenterology & hepatology. 2021 May;18(5):348-64.
Masoud, H. H., Prof, El assal, G., Prof, A. S., Prof, S. Z., Prof, & A. A., Prof (Eds.). (2022, July). Treatment protocol of covid 19 version 1.8 /july 2022 p4.
Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, Moradmand-Badie B, Alinaghi SA, Jahanfar S. Predictors of mortality in patients with COVID-19–a systematic review. European journal of integrative medicine. 2020 Dec 1;40:101226..
Mendonça CV, Mendes Neto JA, Suzuki FA, Orth MS, Machado Neto H, et al. Olfactory dysfunction in COVID-19: a marker of good prognosis?. Brazilian Journal of Otorhinolaryngology. 2022 Jun 27;88:439-44.
Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A,Tabarsi P, et al. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020;10:944---50.
Moghadam AD, Eslami P, Razavi-Khorasani N, Moazzami B, Mousavizadeh M, et al. The impacts of the COVID-19 pandemic on liver transplant patients; time to change the priorities. Archives of Iranian medicine. 2020;23(7):507-8.
National Health Commission of the People’s Republic of China website. Diagnosis and treatment of novel coronavirus infection (trial version 6). National Health Commission of the People’s Republic of China; 2020. Available at: www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. Journal of the renin-angiotensin-aldosterone system: JRAAS. 2020 Apr;21(2).
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England). 2020 Feb 15;395(10223):e30.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020 May 26;323(20):2052-9.
Sadeghi A, Eslami P, Moghadam AD, Pirsalehi A, Shojaee S, Vahidi M, Soheili A, Ghanimat F, Keshmiri Y, Abdi S, Zali MR. COVID-19 and ICU admission associated predictive factors in Iranian patients. Caspian Journal of Internal Medicine. 2020;11(Suppl 1):512.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, et al. Comorbidity and its impact on patients with COVID-19. SN comprehensive clinical medicine. 2020 Aug;2(8):1069-76.
Shi Y, Vanhoutte PM. Macro-and microvascular endothelial dysfunction in diabetes. J Diab 2017; 9:434–449.
Simpson S, Kay FU, Abbara S, et al.. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiol Cardiothorac Imaging. 2020;2(2):e200152.
Situation report - who | world health organization (no date). Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200429-sitrep-100-covid-19.pdf?sfvrsn=bbfbf3d1_6 (Accessed: November 9, 2022).
SPSS Inc. Released 2020. IBM SPSS statistics for windows, version 26.0, Armnok, NY: IBM Corp.
Syed AM, Ciling A, Taha TY, Chen IP, Khalid MM, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proceedings of the National Academy of Sciences. 2022 Aug 2;119(31):e2200592119.
Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck.2020;42:1252---8.
VanBlargan LA, Errico JM, Halfmann P, Zost SJ, Crowe JE, et al. An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. BioRxiv. 2021 Jan 1.
Wang D, Hu B, Hu C, Zhu F, Liu X, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323:1061–1069.
Wang F, Zhang C. What to do next to control the 2019-nCoV epidemic?.Lancet (Lond, Engl) 2020; 395:391–393.
Wang M, Cao R, Zhang L, Yang X, Liu J, et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
Yadaw AS, Li YC, Bose S, Iyengar R, Bunyavanich S, et al. Clinical predictors of COVID-19 mortality. medRxiv. 2020 May 22.
Yu Y, Xu D, Fu S, Zhang J, Yang X, et al.Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Critical care. 2020 Dec;24(1):1-0.
Zeng Z, Yu H, Chen H, Qi W, Chen L, et al.Longitudinal changes ofinflammatory parameters and their correlation with disease severity and outcomesin patients with COVID-19 from Wuhan, China. Critical Care. 2020 Dec;24(1):1-2.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, et al.The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical immunology. 2020 May 1;214:108393.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28;395(10229):1054-62.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
